Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

will pharma sa-nv - ascorbic acid 500 mg - prolonged-release capsule, hard - 500 mg - ascorbic acid 500 mg - ascorbic acid (vit c)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

will pharma sa-nv - ascorbic acid 500 mg - prolonged-release capsule, hard - 500 mg - ascorbic acid 500 mg - ascorbic acid (vit c)

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

will pharma sa-nv - vitamin d3 0,625 mg - eq. cholecalciferol 25000 iu - capsule, soft - 25000 iu - vitamin d3 0.625 mg - colecalciferol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

will pharma sa-nv - vitamin d3 1,25 mg - eq. cholecalciferol 50000 iu - capsule, soft - 50000 iu - vitamin d3 1.25 mg - colecalciferol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

will pharma sa-nv - cholecalciferol 20 µg - capsule, soft - colecalciferol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

will pharma sa-nv - cholecalciferol 25 µg - capsule, soft - colecalciferol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

will pharma sa-nv - cholecalciferol 80 µg - capsule, soft - colecalciferol

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - von willebrand factor human (unii: ze22ne22f1) (von willebrand factor human - unii:ze22ne22f1) - von willebrand factor human 650 [iu] in 5 ml - vonvendi [von willebrand factor (recombinant)] is a recombinant von willebrand factor (rvwf) indicated for use in adults (age 18 and older) diagnosed with von willebrand disease (vwd) for: - on-demand treatment and control of bleeding episodes. - perioperative management of bleeding. - routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe type 3 vwd receiving on-demand therapy. vonvendi is contraindicated in patients who have had life-threatening hypersensitivity reactions to vonvendi or constituents of the product (tri-sodium citrate-dihydrate, glycine, mannitol, trehalose-dihydrate, polysorbate 80, and hamster or mouse proteins) [see description (11)] . risk summary adequate and well-controlled studies with vonvendi have not been conducted in pregnant women. animal developmental and reproductive toxicity studies have not been conducted with vonvendi. it is not known whether vonvendi can cause fetal harm when administered to a pregnant woman or whether it can affect reprodu

United States - English - NLM (National Library of Medicine)

uriel pharmacy inc. - dryopteris filix-mas root (unii: c0zk0rrf5x) (dryopteris filix-mas root - unii:c0zk0rrf5x), pteridium aquilinum whole (unii: 05t3m06hcm) (pteridium aquilinum whole - unii:05t3m06hcm), salix purpurea bark (unii: 287vjo13m9) (salix purpurea bark - unii:287vjo13m9), willow bark (unii: s883j9jdyx) (willow bark - unii:s883j9jdyx), salix alba flower (unii: 905y746bsw) (salix alba flower - unii:905y746bsw), asplenium scolopendrium top (unii: hja3ywq7hl) (asplenium scolopendrium top - unii:hja3ywq7hl) - directions: for oral use only. use: temporary relief of digestive upset.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lfb biopharmaceuticals ltd - von willebrand factor - powder and solvent for solution for injection - 1000unit